The gap between a pharmacy sale that maximises value and one that does not is mostly determined by what happened in the two to three years before the sale, not in the weeks around it. By the time a buyer is at the table, the accounts are what they are, the BADR qualifying conditions either hold or they do not, and the NHS regulatory clock has either started or it has not.
This post sequences the exit by phase: what to tackle early, what belongs in the middle period, what the final twelve months require, and what needs to be in place at completion. The tax figures are cited to source; the value levers are pharmacy-specific. For the readiness checklist (what to fix in your accounts), see preparing a pharmacy for sale. For the deep tax mechanics, see the pharmacy sale CGT and BADR service.
When to start planning a pharmacy exit
Start two to three years before the target disposal date. The biggest levers are a clean, reconciled margin story that supports the price a buyer will pay, the deal structure, and timing the sale around the BADR rate and your CGT position. All three take time to put in place. The BADR qualifying period is at least two years of trading ownership; the NHS contract change-of-ownership process under the 2013 Regulations runs on its own long timeline; and a buyer's due diligence will want three years of clean, reconciled accounts. None of those can be compressed in the final months before exchange.
The exit timeline, phase by phase
The table below sequences the main value actions and tax actions across the exit horizon. It is a planning framework, not a legal or tax opinion; every situation has specific facts that change the calculation.
| Phase | Value action | Tax / structure action | Why it matters |
|---|---|---|---|
| Early (2-3 years out) | Start producing monthly management accounts that separate NHS reimbursement, Drug Tariff margins, OTC retail and service income. Annotate Drug Tariff adjustment months. File FP34 NHSBSA payment schedules. | Check BADR qualifying conditions: two-year ownership, officer/employee status, 5% shares and votes. Note prior use of the £1m lifetime limit. Flag any restructuring planned (it can reset the clock). | Three years of clean accounts is the buyer's minimum. BADR conditions must be met at disposal, so the clock starts now. |
| Mid period (12-24 months out) | Review VAT retail-scheme choice and document the basis. Separate Pharmacy First and other service income as a distinct revenue line. Confirm dispensing item volume trend is evidenced month by month. | Model the expected gain and check whether it is within the BADR £1m lifetime limit, within the basic-rate band, or above. Consider whether deal structure (share vs asset) changes the BADR eligibility or the buyer's stamp duty exposure. Assess whether earn-out or deferred consideration is likely and what that does to the timing of tax. | VAT inconsistency is a due-diligence red flag that transfers on a share purchase. Structure decisions made before heads of terms are signed; reversing them later is costly. |
| Final 12 months | Assemble the three-year margin-story document: revenue by line, Drug Tariff variance annotations, FP34 schedule, VAT-scheme disclosure. Confirm GPhC registration is current and understand the change-of-ownership regulatory steps. | Confirm BADR qualifying conditions still hold. Check remaining lifetime limit. Agree deal structure and earn-out mechanics with advisers before heads of terms. Consider the disposal-date decision in relation to the current tax year and rate. | The margin story is presented to buyers early in the process. The regulatory process under the 2013 Regulations needs to start in parallel with legal, not after it. |
| At completion | Data room is ready: three years of accounts, FP34 schedules, VAT-scheme records, GPhC and NHS contract documentation, employee records. | Exchange date determines the BADR rate and the tax year. Any deferred consideration or earn-out is tracked separately; CGT on each payment falls due in the year that payment crystallises. File the CGT return within 60 days of completion for residential elements; annual Self Assessment for the rest. | A buyer's due-diligence team will interrogate every line. Delays from missing records push completion back and can reopen price negotiation. |
The tax-timing lever: BADR, CGT bands and the disposal date
Business Asset Disposal Relief reduces the CGT rate to 18% for 2026/27 on qualifying gains up to the £1m lifetime limit per person. The rate was 14% in 2025/26 and 10% before that. The disposal date (normally the exchange date, not completion) determines which rate applies.
For gains beyond the BADR limit, or where BADR does not apply, standard CGT rates are 18% within the remaining basic-rate band and 24% above it. The basic-rate band ceiling is £37,700. The annual exempt amount is frozen at £3,000.
| Gain type | Rate for 2026/27 | Notes |
|---|---|---|
| BADR-qualifying (up to £1m lifetime limit) | 18% | Qualifying conditions must be met at exchange; lifetime limit is per person, not per company |
| Standard CGT within remaining basic-rate band | 18% | Basic-rate band ceiling £37,700; income for the year is taken into account first |
| Standard CGT above basic-rate band | 24% | Applies to the excess; pharmacy is a non-residential asset for the rate split |
| Annual exempt amount | £3,000 deducted from total gain | Frozen; modest at typical pharmacy gain values |
Sources: gov.uk/business-asset-disposal-relief and gov.uk/capital-gains-tax/rates.
Where a sale involves earn-out or deferred consideration, the CGT does not all fall due at exchange. A gain on each deferred payment is generally taxed in the year that payment is received or the right to it becomes unconditional. This can spread the liability across tax years and interact differently with the basic-rate band in each year. The timing of deferred payments relative to your other income in those years is a planning variable worth running properly, subject to your specific facts.
Timing around the BADR rate step and your CGT band can be material, subject to your facts. Do not treat disposal timing as a formality. For a modelled computation, visit the pharmacy sale CGT and BADR service page or speak to us directly.
The value levers: what to fix early so the accounts tell the right story
Pharmacy valuation is anchored on the quality and defensibility of the income, not just its size. A buyer is acquiring the NHS contract and the income stream it generates; the physical premises and stock are secondary. The value levers that determine how a buyer reads that income are within an owner's control, but they take time to fix.
Category M and Drug Tariff margin story
Under the Drug Tariff and Category M mechanism, gross margin is set centrally and retrospectively adjusted. A buyer's accountant will test whether margin swings are explained or unexplained. Unexplained variance is priced in as risk, which means a lower offer. The fix is management-account annotations that record which months were affected by Drug Tariff adjustments and why, so the variance is transparent, not suspicious.
Dispensing volume (items per month) is the proxy a buyer uses for NHS contract strength. A consistent or growing volume trend over three years is the strongest account-level signal that the contract income is durable. Start tracking it as a formal management metric now if it is not already.
FP34 and NHS income cleanliness
The FP34 NHSBSA payment cycle drives pharmacy cash flow: prescriptions submitted monthly, payment arriving roughly two months later with an advance on account. Three years of FP34 payment schedules reconciled to bank statements is the minimum a buyer's due diligence requires. Missing months, unreconciled advances, or gaps in the payment log are due-diligence red flags that delay completion and invite price chip.
Income coding matters too. Pharmacy First and other service income should be coded as a separate line from NHS reimbursement and remuneration. A buyer paying for a growing service line cannot verify it if it is buried in a catch-all income code.
VAT mix and retail-scheme consistency
A community pharmacy is a VAT-mixed business: NHS-dispensed prescription drugs are zero-rated; most OTC retail is standard-rated. The retail scheme chosen to split takings must be appropriate and consistently applied across the three years the buyer will scrutinise. On a share purchase, inconsistent VAT treatment transfers as an audit risk to the buyer; they will either price it in or require a warranty. Reviewing and documenting the scheme basis early removes this risk from the negotiation.
Goodwill and what drives it
Goodwill dominates pharmacy pricing because what a buyer is acquiring is primarily the NHS contract and the item volume it supports. For a buyer acquiring via a company purchase, corporation tax relief on goodwill is restricted and available only in limited cases at fixed rates. This affects the buyer's after-tax economics and can influence whether they prefer a share purchase or an asset deal. Understanding the goodwill position from the seller's side helps anticipate how a buyer will structure their offer.
For the mechanics of how pharmacy goodwill is assessed, see the pharmacy goodwill valuation post.
Structure and the contract-transfer reality
The deal structure decision sits between two options, each with different tax and regulatory implications.
A share purchase means the buyer acquires the company and its full history: liabilities, warranties, VAT records, employment obligations and all. Stamp duty is 0.5% on the share consideration. Source: gov.uk/tax-buy-shares. The NHS contract stays with the company, which simplifies the regulatory position but means the buyer inherits the company's past.
An asset purchase means the buyer selects which assets to acquire. If property transfers, SDLT applies at non-residential and mixed-use rates, reaching 5% on the slice above £250,000. The buyer does not inherit the company's history, but the NHS contract position is more complex because the contract is held by the entity, not the assets.
In either case, the NHS contract does not transfer automatically. Under the NHS (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013, a change of ownership requires NHS England approval. The process takes time and must run in parallel with the legal completion process, not after it. Triggering it early and building it into the overall transaction plan prevents it from becoming the delay that holds up completion.
GPhC registration requirements for a change of ownership also apply. If the buyer is a company, there are superintendent pharmacist requirements to meet. These are regulatory steps that need to be mapped at the start of the final twelve months, not discovered at the point of exchange.
Structure decisions and their tax consequences interact with BADR eligibility: a sale of shares in a personal company has different conditions from a sale of a sole-trader or partnership business. The structure should be agreed, with specialist input, before heads of terms are signed. For a full treatment of the share versus asset decision, see the share vs asset purchase post.
What a specialist does across the timeline
Exit planning over a two to three year horizon is not a one-off engagement. The work that moves the outcome spans phases.
In the early period, the specialist role is diagnostic: checking BADR qualifying conditions, reviewing the accounts coding, and flagging restructuring risks before they are accidentally triggered. In the mid period, it is modelling: running a gain estimate against the lifetime limit, the basic-rate band, and the expected deal structure so there are no surprises at heads of terms. In the final twelve months, it is co-ordination: preparing the data-room accounts, running the margin-story document, timing the disposal date decision, and managing the regulatory and legal workstreams in parallel.
At completion, the CGT computation and filing obligations (within 60 days for any residential element; Self Assessment for the main gain) are live deadlines with penalties for late filing. The post-deal period also includes any earn-out tracking, warranty and indemnity positions, and the closing of the company if the sale was a share deal and the buyer then winds the entity down.
The selling a pharmacy hub sets out how specialist support maps across the sale process. To talk through the timeline for your situation and run an initial sense-check on the BADR and CGT position, get in touch or see the pharmacy sale CGT and BADR service page.